Inspira Technologies Completes Clinical Study for HYLA Blood Sensor

Inspira Technologies Oxy BHN ( (IINN) ) has issued an update.

On November 13, 2025, Inspira Technologies announced the completion of a clinical study for its HYLA blood sensor, a non-invasive device designed for real-time blood monitoring. The study showed accuracy levels between 95% to 99%, and the company is now moving towards final validation and regulatory submission. This development enhances Inspira’s market positioning by potentially offering a disruptive solution in critical-care environments, supporting patient safety and workflow efficiency.

The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.

The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The company offers the FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. It is also developing the HYLA blood sensor platform for continuous, non-invasive monitoring, positioning itself as a significant player in the life-support and MedTech landscape.

Average Trading Volume: 685,141

Technical Sentiment Signal: Sell

Current Market Cap: $25.11M

Learn more about IINN stock on TipRanks’ Stock Analysis page.